NewAmsterdam Pharma Co N.V. 8-K

What Happened
NewAmsterdam Pharma Company N.V. announced on April 24, 2026 that Chief Accounting Officer Louise Kooij’s employment will end effective August 31, 2026. The company and Ms. Kooij entered a separation agreement that specifies post‑separation payments, extensions of equity vesting and option exercise periods, and standard restrictive covenants.

The Separation Agreement (entered April 24, 2026) provides a lump‑sum cash payment equal to 12 months of Ms. Kooij’s current base salary, a pro‑rated 2026 annual cash bonus at target through the separation date, payment for accrued unused holiday/vacation under Dutch law, extension of outstanding equity vesting through January 10, 2027, and an option exercise deadline of February 10, 2027. The agreement also includes confidentiality, non‑compete, non‑disparagement provisions and a release of claims. The company will file the full Separation Agreement as an exhibit to its Form 10‑Q for the quarter ending June 30, 2026.

Key Details

• Departure effective: August 31, 2026; agreement executed April 24, 2026.
• Cash: lump sum = 12 months base salary; plus pro‑rated 2026 bonus (at target) and accrued holiday pay.
• Equity: vesting of outstanding options and RSUs extended through Jan 10, 2027; vested options must be exercised by Feb 10, 2027.
• Contains restrictive covenants (confidentiality, non‑compete, non‑disparagement) and release of claims.

Why It Matters
This is a material executive change in the company’s accounting leadership that may affect finance and reporting continuity until a replacement is named. The separation will create a defined near‑term cash and potential compensation-related cost (salary, bonus, and equity treatment), though the filing does not state dollar amounts. Investors should watch for the company’s disclosure of a successor CAO and review the full Separation Agreement in the upcoming Form 10‑Q for additional details.